FR2475572A1 - Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications - Google Patents
Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications Download PDFInfo
- Publication number
- FR2475572A1 FR2475572A1 FR8002978A FR8002978A FR2475572A1 FR 2475572 A1 FR2475572 A1 FR 2475572A1 FR 8002978 A FR8002978 A FR 8002978A FR 8002978 A FR8002978 A FR 8002978A FR 2475572 A1 FR2475572 A1 FR 2475572A1
- Authority
- FR
- France
- Prior art keywords
- virus
- preparation
- chloroform
- concentration
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 241000700605 Viruses Species 0.000 title claims abstract description 43
- 239000000427 antigen Substances 0.000 title claims abstract description 42
- 102000036639 antigens Human genes 0.000 title claims abstract description 42
- 108091007433 antigens Proteins 0.000 title claims abstract description 42
- 230000008569 process Effects 0.000 title claims abstract description 32
- 239000012634 fragment Substances 0.000 title claims abstract description 26
- 229960005486 vaccine Drugs 0.000 title abstract description 33
- 210000004779 membrane envelope Anatomy 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 48
- 239000003599 detergent Substances 0.000 claims abstract description 38
- 210000002845 virion Anatomy 0.000 claims abstract description 35
- 239000000725 suspension Substances 0.000 claims abstract description 17
- -1 HALOGEN HYDROCARBON Chemical class 0.000 claims abstract description 10
- 230000007935 neutral effect Effects 0.000 claims abstract description 6
- 238000013019 agitation Methods 0.000 claims abstract description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 70
- 241000712461 unidentified influenza virus Species 0.000 claims description 30
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 19
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 18
- 229920000053 polysorbate 80 Polymers 0.000 claims description 18
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 16
- 229940068968 polysorbate 80 Drugs 0.000 claims description 16
- 230000009172 bursting Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 229960003971 influenza vaccine Drugs 0.000 claims description 11
- 239000012429 reaction media Substances 0.000 claims description 11
- 238000005194 fractionation Methods 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
- 230000000415 inactivating effect Effects 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000002270 exclusion chromatography Methods 0.000 claims description 7
- 229960000380 propiolactone Drugs 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000008282 halocarbons Chemical class 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 241000004176 Alphacoronavirus Species 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000005352 clarification Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 125000006353 oxyethylene group Chemical group 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract description 5
- 229930195733 hydrocarbon Natural products 0.000 abstract description 5
- 206010022000 influenza Diseases 0.000 abstract description 4
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- 101710154606 Hemagglutinin Proteins 0.000 description 19
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 19
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 19
- 101710176177 Protein A56 Proteins 0.000 description 19
- 239000000185 hemagglutinin Substances 0.000 description 19
- 108010006232 Neuraminidase Proteins 0.000 description 18
- 102000005348 Neuraminidase Human genes 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000470 constituent Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000000601 reactogenic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000206607 Porphyra umbilicalis Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 230000001492 haemagglutinating effect Effects 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000148815 Leucozonella rubens Species 0.000 description 1
- 108010004718 Lipoglycopeptides Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940126581 whole-virion vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8002978A FR2475572A1 (fr) | 1980-02-11 | 1980-02-11 | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
| CA000358547A CA1158978A (en) | 1980-02-11 | 1980-08-19 | Process for obtaining lipid envelope virus subunits, notably antigens for use as vaccines, the products obtained and their applications |
| US06/636,791 US4522809A (en) | 1980-02-11 | 1984-08-01 | Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8002978A FR2475572A1 (fr) | 1980-02-11 | 1980-02-11 | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2475572A1 true FR2475572A1 (fr) | 1981-08-14 |
| FR2475572B1 FR2475572B1 (OSRAM) | 1982-02-19 |
Family
ID=9238454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8002978A Granted FR2475572A1 (fr) | 1980-02-11 | 1980-02-11 | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4522809A (OSRAM) |
| CA (1) | CA1158978A (OSRAM) |
| FR (1) | FR2475572A1 (OSRAM) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522809A (en) * | 1980-02-11 | 1985-06-11 | Institut Pasteur | Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications |
| EP0431129A4 (en) * | 1989-06-15 | 1992-03-11 | Rorer International (Overseas) Inc | Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions |
| WO1992017570A1 (fr) * | 1991-03-29 | 1992-10-15 | Vegatec | Procede d'inactivation de virus et composition pharmaceutique pour l'inactivation de virus |
| WO1996005294A1 (fr) * | 1994-08-16 | 1996-02-22 | Pasteur Merieux Serums Et Vaccins | Procede de preparation du virus grippal, antigens obtenus et leurs applications |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0232410A4 (en) * | 1985-08-15 | 1988-01-25 | Amgen | CLEAVAGE PROCESS AND BUFFER FOR THE EXTRACTION OF HEPATITIS B SURFACE ANTIGENS FROM YEAR CELLS. |
| US4790987A (en) * | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
| US4789545A (en) * | 1986-03-31 | 1988-12-06 | New York Blood Center, Inc. | Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof |
| NZ224422A (en) * | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| US5236840A (en) * | 1990-01-18 | 1993-08-17 | University Of Hawaii | Method for growing crustacean virus in fish cells |
| AUPN030794A0 (en) | 1994-12-22 | 1995-01-27 | Aruba International Pty Ltd | Discontinuous plasma or serum delipidation |
| US7439052B2 (en) * | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| US7407663B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| US20090017069A1 (en) * | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| PL362964A1 (en) * | 2000-10-02 | 2004-11-02 | Glaxosmithkline Biologicals S.A. | Vaccine |
| JP2004532709A (ja) * | 2001-06-25 | 2004-10-28 | リピド サイエンスィズ インコーポレイテッド | 流体から脂質を除去するための溶媒を用いたシステムおよび方法 |
| US7033500B2 (en) * | 2001-06-25 | 2006-04-25 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US20030127386A1 (en) * | 2001-06-25 | 2003-07-10 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
| US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20060060520A1 (en) * | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| US20040106556A1 (en) * | 2002-08-26 | 2004-06-03 | Yanhong Zhu | Method of treating and preventing alzheimer disease through administration of delipidated protein and lipoprotein particles |
| JP2007527387A (ja) * | 2003-07-03 | 2007-09-27 | リピッド サイエンシーズ，インコーポレイテッド | 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置 |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| US6960803B2 (en) * | 2003-10-23 | 2005-11-01 | Silicon Storage Technology, Inc. | Landing pad for use as a contact to a conductive spacer |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| CA2696090C (en) * | 2007-08-28 | 2017-06-13 | Baxter International Inc. | Method for producing viral vaccines |
| KR101549296B1 (ko) | 2010-04-14 | 2015-09-01 | 이엠디 밀리포어 코포레이션 | 고역가 고순도 바이러스 스톡의 생산 방법 및 이의 사용 방법 |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| EP3714039B1 (en) | 2017-11-22 | 2025-03-12 | HDL Therapeutics, Inc. | Methods for priming fluid circuits of a plasma processing system |
| JP2021509894A (ja) | 2017-12-28 | 2021-04-08 | エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ヒト血漿から抽出されたｐｒｅ−β高密度リポタンパク質を保存および投与するための方法 |
| US11369675B2 (en) | 2018-01-22 | 2022-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1587316A (OSRAM) * | 1964-03-20 | 1970-03-20 | ||
| FR2248054A1 (OSRAM) * | 1973-10-18 | 1975-05-16 | Flockhart & Co | |
| FR2422720A2 (fr) * | 1977-04-26 | 1979-11-09 | Elf Aquitaine | Separation et purification de proteines par chromatographie |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847737A (en) * | 1965-03-22 | 1974-11-12 | A Kanarek | Inactivation of myxoviruses and method of preparing a vaccine therefrom |
| US3639578A (en) * | 1970-02-18 | 1972-02-01 | Int Minerals & Chem Corp | Virus insecticide |
| FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
-
1980
- 1980-02-11 FR FR8002978A patent/FR2475572A1/fr active Granted
- 1980-08-19 CA CA000358547A patent/CA1158978A/en not_active Expired
-
1984
- 1984-08-01 US US06/636,791 patent/US4522809A/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1587316A (OSRAM) * | 1964-03-20 | 1970-03-20 | ||
| FR2248054A1 (OSRAM) * | 1973-10-18 | 1975-05-16 | Flockhart & Co | |
| FR2422720A2 (fr) * | 1977-04-26 | 1979-11-09 | Elf Aquitaine | Separation et purification de proteines par chromatographie |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522809A (en) * | 1980-02-11 | 1985-06-11 | Institut Pasteur | Process for obtaining lipid envelope virus sub-units, notably antigens for use as vaccines, the products obtained and their applications |
| EP0431129A4 (en) * | 1989-06-15 | 1992-03-11 | Rorer International (Overseas) Inc | Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions |
| WO1992017570A1 (fr) * | 1991-03-29 | 1992-10-15 | Vegatec | Procede d'inactivation de virus et composition pharmaceutique pour l'inactivation de virus |
| WO1996005294A1 (fr) * | 1994-08-16 | 1996-02-22 | Pasteur Merieux Serums Et Vaccins | Procede de preparation du virus grippal, antigens obtenus et leurs applications |
| FR2723740A1 (fr) * | 1994-08-16 | 1996-02-23 | Pasteur Merieux Serums Vacc | Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1158978A (en) | 1983-12-20 |
| FR2475572B1 (OSRAM) | 1982-02-19 |
| US4522809A (en) | 1985-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2475572A1 (fr) | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications | |
| US5698432A (en) | Vaccines and methods for their production | |
| JP5754860B2 (ja) | ワクチンアジュバントの製造の間の親水性濾過 | |
| JP5820390B2 (ja) | エマルジョンの微小流動化中および／または均質化中における成分の循環 | |
| JP4074582B2 (ja) | 新規なワクチン | |
| AU701024B2 (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
| AU2001238478A1 (en) | Proteosome influenza vaccine | |
| WO2001060402A2 (en) | Proteosome influenza vaccine | |
| AU2004211869B2 (en) | Virosome-like-particles | |
| CN102781469A (zh) | 用于生产流感疫苗的方法 | |
| RU2710239C1 (ru) | Способ получения антигена или антигенов для производства противогриппозной вакцины и вакцина на его основе | |
| EP0841942A1 (fr) | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu | |
| EP0041880B1 (fr) | Procédé pour isoler des antigènes glycoprotéiques viraux et son application à la préparation de vaccins | |
| BE1023903B1 (fr) | Nouveau procédé | |
| JP5843615B2 (ja) | 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製 | |
| FR3119541A1 (fr) | Préparation, propriétés et applications de compositions médicamenteuses contenant des globulines sériques dotées d’activités antivirales | |
| RU2429015C2 (ru) | Способ получения продукта, содержащего иммуноглобулины g, a, m (варианты) | |
| DE3005495C2 (de) | Herstellung von Fragmenten von Viren mit Lipidhülle und sie enthaltende Arzneimittelzubereitungen | |
| RU2804948C2 (ru) | Пентавалентная субъединичная вакцина против респираторных инфекций и способ ее получения | |
| WO1994000557A1 (fr) | Procede d'obtention de proteines membranaires, permettant le maintien des structures oligomeriques de ces proteines en conditions denaturantes, et utilisation de ces proteines dans un but de diagnostic ou de vaccination | |
| RU2741003C1 (ru) | Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов | |
| EP0080412B1 (fr) | Vaccin anti-aphteux et anti-colibacillaire et son procédé de préparation | |
| FR2667245A1 (fr) | Association vaccinale contre les pathogenes infectieux. | |
| FR2671974A1 (fr) | Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal. | |
| RU2604414C2 (ru) | Живая вакцина для профилактики гриппа и способ ее получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |